Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Top Cited Papers
- 13 May 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 21 (6), 796-807
- https://doi.org/10.1016/s1470-2045(20)30157-1
Abstract
No abstract availableFunding Information
- Agios Pharmaceuticals
This publication has 25 references indexed in Scilit:
- Second-line chemotherapy in advanced biliary cancer: a systematic reviewAnnals Of Oncology, 2014
- Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancerNature, 2014
- Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomasOncogene, 2012
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor GenotypingThe Oncologist, 2011
- Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21British Journal of Cancer, 2011
- Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation studyBMC Medical Research Methodology, 2011
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH).British Journal of Clinical Pharmacology, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993